Even Amylin deal pushed by Carl Ichan took from April 26th to June 30th--original bid in Feb.
Original bid June 30th,2013--we are 7-8 weeks from that date.
DEAL will take more time to iron out legal details. If Onyx accepts a deal at 130$/share--there will be LAWSUIT against the CEO and the Directors.
I now guess competing bids of 140 in cash by Amgen and 130 cash + 20 CSR with AZN; NVS and BMS, Merck and Pfizer are dark horses at 150 cash. Kyprolis has an established mechanism of action like Velcade and it is just a matter of the trial size and length. Nerve sparing is a slam dunk. The bias CV and renal story raised by Reuters is old news and the same problem for Velcade just benefit vs risk. You cannot manage the 30% nerve damage with Velcade. Nexavar in breast ca for Europe is also not factored and will be a major cash cow. The long-term cash flow with expanded Stivarga labeling with no COG and ramping Nexavar sales alone justify the price to ensure breaking even at worst with little risk. There is plenty of headcount and overhead for slashing to squeeze out additional savings to meet earnings expectations as needed, and significant Onxx cash on-hand. I hope AZN takes the plunge instead of say merging and consolidating with BMS and clashing cultures.